Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up

Area of Science:

• Neuro-oncology
• Cancer Pharmacology
• Molecular Biology

Background:

• Brain cancer treatment is largely ineffective due to poor drug delivery.
• P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) efflux transporters impede anti-cancer drugs at the blood-brain and blood-tumor barriers.
• These transporters are present in brain tumor cells and brain tumor stem-like cells.

Purpose of the Study:

• To review strategies for overcoming P-gp and BCRP mediated drug resistance in brain cancer.
• To explore targeting transporter regulation and direct transporter inhibition.
• To discuss the cooperative role of P-gp and BCRP as gatekeepers at the blood-brain barrier.

Main Methods:

• Review of current literature on signaling pathways affecting P-gp and BCRP.
• Analysis of the "cooperative gatekeeper" model of P-gp and BCRP at the blood-brain barrier.
• Summary of recent advancements in dual P-gp/BCRP inhibitors.

Main Results:

• Signaling pathways offer potential targets to down-regulate P-gp and BCRP expression and activity.
• P-gp and BCRP function cooperatively to restrict drug entry into the brain.
• Development of dual inhibitors targeting both P-gp and BCRP is a promising therapeutic avenue.

Conclusions:

• Overcoming P-gp and BCRP efflux is crucial for effective brain cancer chemotherapy.
• Targeting transporter regulation and inhibition, particularly dual inhibition, holds significant therapeutic potential.
• Future research should focus on novel strategies to enhance drug delivery across the blood-brain barrier.